Qiang Ding

Qiang (Peter) Ding is a co-founder and CEO of Allorion Therapeutics since June 2020, specializing in small molecule drug discovery for autoimmune diseases and cancer with innovative technologies. Prior to this role, Qiang co-founded Curegenix in June 2011, where as R&D Head, led the discovery and development of CGX1321, a first-in-class small molecule WNT inhibitor currently in Phase Ib/II clinical trials. Qiang's earlier experience includes serving as a Research Investigator II at GNF from June 2000 to May 2011, where leadership was provided in kinase inhibitor drug discovery and regenerative medicine projects. Qiang's educational background includes degrees from Rutgers University and Peking University.